Saxena Ruchi, Gottlin Elizabeth B, Campa Michael J, Bushey Ryan T, Guo Jian, Patz Edward F, He You-Wen
Department of Integrative Immunobiology, Duke University School of Medicine, Durham, NC, United States.
Department of Radiology, Duke University School of Medicine, Durham, NC, United States.
Front Cell Dev Biol. 2024 Feb 8;12:1302490. doi: 10.3389/fcell.2024.1302490. eCollection 2024.
The elimination of cancer cells critically depends on the immune system. However, cancers have evolved a variety of defense mechanisms to evade immune monitoring, leading to tumor progression. Complement factor H (CFH), predominately known for its function in inhibiting the alternative pathway of the complement system, has recently been identified as an important innate immunological checkpoint in cancer. CFH-mediated immunosuppression enhances tumor cells' ability to avoid immune recognition and produce an immunosuppressive tumor microenvironment. This review explores the molecular underpinnings, interactions with immune cells, clinical consequences, and therapeutic possibilities of CFH as an innate immune checkpoint in cancer control. The difficulties and opportunities of using CFH as a target in cancer immunotherapy are also explored.
癌细胞的清除严重依赖于免疫系统。然而，癌症已经进化出多种防御机制来逃避免疫监视，从而导致肿瘤进展。补体因子H（CFH），主要因其在抑制补体系统替代途径中的作用而闻名，最近被确定为癌症中一个重要的先天性免疫检查点。CFH介导的免疫抑制增强了肿瘤细胞避免免疫识别的能力，并产生免疫抑制性肿瘤微环境。本文综述探讨了CFH作为癌症控制中先天性免疫检查点的分子基础、与免疫细胞的相互作用、临床后果以及治疗可能性。还探讨了将CFH作为癌症免疫治疗靶点的困难和机遇。
